Gene: WNT5A

7474
hWNT5A
Wnt family member 5A
protein-coding
3p14.3
Ensembl:ENSG00000114251 MIM:164975 Vega:OTTHUMG00000158361 UniprotKB:P41221
NG_031992.1
PubMed
0   ANCO-SNPs
ND
4   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.642e-1 (AD)  3.243e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PTBP30.747
LCP20.732
MAFB0.718
KCNK130.717
RAB11FIP10.717
ADAM90.713
TMEM87B0.711
USP150.709
MIS18BP10.707
RB10.706

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SOX3-0.357
NTSR2-0.334
IZUMO4-0.305
S100A1-0.304
OR4F5-0.304
LFNG-0.303
HES6-0.298
PAQR6-0.294
RBP1-0.294
HHATL-0.292

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of WNT5A mRNA"28903501
C0512461-methylanthracene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of WNT5A mRNA28329830
C4656642-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide inhibits the reaction [WNT5A protein results in increased expression of AQP5 protein]26833564
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in increased expression of WNT5A mRNA"25614096
C0140242,4,5,2',4',5'-hexachlorobiphenyl"2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of WNT5A mRNA"22262711
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of WNT5A mRNA"22262711
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of WNT5A mRNA"23196670
C5830744,4'-hexafluorisopropylidene diphenol"4,4'-hexafluorisopropylidene diphenol results in decreased expression of WNT5A mRNA"25912373
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
D000079AcetaldehydeAcetaldehyde affects the expression of WNT5A mRNA22634333
D000242Cyclic AMPWNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP]20685861
D000242Cyclic AMPWNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]20685861
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of WNT5A mRNA22100608|2715375
D006710HomocysteineHomocysteine results in decreased expression of WNT5A mRNA17320366
D000643Ammonium ChlorideAmmonium Chloride affects the expression of WNT5A mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of WNT5A mRNA24449571
D001152ArsenicalsArsenicals affects the acetylation of WNT5A promoter19061910
C015001arsenitearsenite results in increased expression of WNT5A mRNA19061910
D001374AzacitidineAzacitidine results in increased expression of WNT5A mRNA20823114
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of WNT5A mRNA20064835|2180250
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of WNT5A protein21802500
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of WNT5A mRNA22228805
D004958Estradiol[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA20823114
D004958Estradiol[Estradiol co-treated with Progesterone] results in decreased expression of WNT5A mRNA20660070
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of WNT5A mRNA19619570
D004958EstradiolEstradiol results in increased expression of WNT5A mRNA19619570
D004958EstradiolEstradiol results in increased expression of WNT5A mRNA19484750
D004958Estradiol[bisphenol A co-treated with Estradiol] results in increased expression of WNT5A mRNA26496021
C543008bis(4-hydroxyphenyl)sulfonebis(4-hydroxyphenyl)sulfone results in decreased expression of WNT5A mRNA25912373
C006780bisphenol Abisphenol A results in increased expression of WNT5A mRNA26364221
C006780bisphenol Abisphenol A results in decreased expression of WNT5A mRNA16029874|2768578
C006780bisphenol Abisphenol A affects the methylation of WNT5A promoter27334623
C006780bisphenol Abisphenol A results in increased expression of WNT5A mRNA24465770
C006780bisphenol A[bisphenol A co-treated with Estradiol] results in increased expression of WNT5A mRNA26496021
C006780bisphenol Abisphenol A results in decreased expression of WNT5A mRNA25181051
D002118CalciumCalcium results in increased expression of WNT5A mRNA24658506
D002118CalciumCalcium results in increased secretion of WNT5A protein24658506
D002118CalciumCASR mutant form inhibits the reaction [Calcium results in increased expression of WNT5A protein]24658506
D002118CalciumWNT5A protein promotes the reaction [Calcium results in increased expression of KRT1 mRNA]24658506
D002118CalciumWNT5A protein promotes the reaction [Calcium results in increased expression of KRT1 protein]24658506
D002118CalciumWNT5A protein promotes the reaction [Calcium results in increased expression of LOR mRNA]24658506
D002118CalciumWNT5A protein promotes the reaction [Calcium results in increased expression of LOR protein]24658506
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of WNT5A mRNA16780995
D002330CarmustineWNT5A mRNA affects the susceptibility to Carmustine16365179
C054133casticincasticin results in decreased expression of WNT5A mRNA27862857
C084597chlorcyclizinechlorcyclizine results in increased expression of WNT5A mRNA21058326
D004390ChlorpyrifosChlorpyrifos results in decreased expression of WNT5A mRNA18502319
D002994ClofibrateClofibrate results in increased expression of WNT5A mRNA23811191
D003042CocaineHDAC5 affects the reaction [Cocaine affects the expression of WNT5A mRNA]17988634
D016572CyclosporineCyclosporine results in decreased expression of WNT5A mRNA20106945|2214713
D016572CyclosporineCyclosporine results in increased expression of WNT5A mRNA27989131
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of WNT5A mRNA23914054
D003976DiazinonDiazinon affects the expression of WNT5A mRNA18502319
D003976DiazinonDiazinon results in decreased expression of WNT5A mRNA19130878
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of WNT5A mRNA21266533
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of WNT5A mRNA25213187
D003994Bucladesine[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA20823114
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of WNT5A mRNA27392435
D004026DieldrinDieldrin results in decreased expression of WNT5A mRNA19130878
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of WNT5A mRNA15070830|1507314
D004054DiethylstilbestrolWNT5A protein affects the reaction [Diethylstilbestrol results in decreased expression of HOXA10 mRNA]15073149
D004054DiethylstilbestrolWNT5A protein affects the reaction [Diethylstilbestrol results in decreased expression of HOXA11 mRNA]15073149
D004054DiethylstilbestrolWNT5A protein affects the reaction [Diethylstilbestrol results in decreased expression of WNT7A mRNA]15073149
D002117CalcitriolCalcitriol results in increased expression of WNT5A mRNA16002434
D004237DiuronDiuron results in increased expression of WNT5A mRNA21551480
D004317DoxorubicinDoxorubicin results in decreased expression of WNT5A mRNA25896364
D004365Drugs, Chinese Herbal"Drugs, Chinese Herbal results in increased expression of WNT5A mRNA"23262642
C045651epigallocatechin gallateepigallocatechin gallate results in increased expression of WNT5A mRNA22079256
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WNT5A mRNA22079256
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of WNT5A mRNA16551644
C007738fluoranthene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of WNT5A mRNA28329830
C061365flusilazoleflusilazole affects the expression of WNT5A mRNA22634333
C061365flusilazoleflusilazole results in decreased expression of WNT5A mRNA28263823
D005492Folic AcidFolic Acid affects the expression of WNT5A mRNA17320366
C056507gemcitabinegemcitabine results in decreased expression of WNT5A mRNA17039268
D019833GenisteinGenistein results in increased expression of WNT5A mRNA21810550
D019833GenisteinGenistein results in decreased expression of WNT5A mRNA17341692
D005947GlucoseGlucose results in increased expression of WNT5A mRNA29163160
D005947GlucoseGlucose results in decreased expression of WNT5A mRNA18004065
D005947GlucoseSimvastatin inhibits the reaction [Glucose results in decreased expression of WNT5A mRNA]18004065
C010974glyphosateglyphosate affects the expression of WNT5A protein28780397
C010974glyphosateglyphosate results in decreased expression of WNT5A mRNA26688330
C010974glyphosateglyphosate results in decreased expression of WNT5A protein26688330
C010974glyphosateWNT5A protein results in decreased susceptibility to glyphosate26688330
C010176halofuginonehalofuginone results in increased expression of WNT5A mRNA17180598
D017313FenretinideFenretinide results in decreased expression of WNT5A mRNA28973697
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of WNT5A mRNA20044591
C031927hydroquinonehydroquinone results in increased expression of WNT5A mRNA22960397
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of WNT5A mRNA27392435
C544151jinfukangjinfukang results in decreased expression of WNT5A mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of WNT5A mRNA24796395|2530787
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of WNT5A mRNA26644586
D017258Medroxyprogesterone Acetate[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA20823114
D017258Medroxyprogesterone AcetateMedroxyprogesterone Acetate results in increased expression of WNT5A mRNA20685861
D017258Medroxyprogesterone AcetateWNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP]20685861
D017258Medroxyprogesterone AcetateWNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]20685861
C042720mercuric bromidemercuric bromide results in increased expression of WNT5A mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
D008727MethotrexateMethotrexate results in increased expression of WNT5A mRNA17320366
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of WNT5A mRNA28001369
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine affects the methylation of WNT5A promoter"26251327
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of WNT5A mRNA"26251327
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of WNT5A mRNA"20188158
D008770MethylnitrosoureaMethylnitrosourea results in increased expression of WNT5A mRNA17341692
D015735MifepristoneMifepristone results in increased expression of WNT5A mRNA17584828
D016685MitomycinWNT5A protein affects the susceptibility to Mitomycin16217747
C406082monomethylarsonous acidmonomethylarsonous acid affects the expression of WNT5A mRNA20886546
C406082monomethylarsonous acidmonomethylarsonous acid results in increased expression of WNT5A mRNA19061910|2210804
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of WNT5A mRNA"25554681
D009532NickelNickel results in increased expression of WNT5A mRNA19130878
C029938nickel sulfatenickel sulfate results in increased expression of WNT5A mRNA22714537
C007350nitrofennitrofen results in increased expression of WNT5A mRNA20006014
C007350nitrofennitrofen results in increased expression of WNT5A protein20006014
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of WNT5A mRNA26272509
C471071perfluorohexanesulfonic acidperfluorohexanesulfonic acid results in decreased expression of WNT5A mRNA22790973
C101814perfluoro-n-undecanoic acidperfluoro-n-undecanoic acid results in increased expression of WNT5A mRNA23602845
D010634PhenobarbitalPhenobarbital affects the expression of WNT5A mRNA19159669
D010634PhenobarbitalNR1I3 protein promotes the reaction [Phenobarbital results in increased expression of WNT5A mRNA]19482888
D010634PhenobarbitalPhenobarbital results in increased expression of WNT5A mRNA19482888
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of WNT5A mRNA26272509
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of WNT5A mRNA19710929
C006253pirinixic acidpirinixic acid results in increased expression of WNT5A mRNA18301758
D010936Plant ExtractsPlant Extracts results in decreased expression of WNT5A mRNA23557933
D010936Plant ExtractsPlant Extracts results in increased expression of WNT5A mRNA23262642
D059808PolyphenolsPolyphenols results in decreased expression of WNT5A mRNA16293270
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WNT5A mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of WNT5A mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of WNT5A mRNA22714537
D011374Progesterone[Estradiol co-treated with Progesterone] results in decreased expression of WNT5A mRNA20660070
D011441PropylthiouracilPropylthiouracil affects the expression of WNT5A mRNA24780913
C004532quinonequinone results in increased expression of WNT5A mRNA22960397
D020849Raloxifene Hydrochloride[Raloxifene Hydrochloride co-treated with ESR2 protein] results in decreased expression of WNT5A mRNA19059307
C059514resveratrolresveratrol results in decreased expression of WNT5A mRNA25061499
C059514resveratrolresveratrol results in decreased expression of WNT5A protein25061499
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of WNT5A mRNA23806026
D012822Silicon DioxideSilicon Dioxide results in decreased expression of WNT5A mRNA25351596|2709509
D012822Silicon DioxideSilicon Dioxide results in decreased expression of WNT5A protein27095093
D019821SimvastatinSimvastatin inhibits the reaction [Glucose results in decreased expression of WNT5A mRNA]18004065
D019821SimvastatinSimvastatin results in increased expression of WNT5A mRNA19968183
D019821SimvastatinSimvastatin results in increased expression of WNT5A protein18004065
C009277sodium arsenatesodium arsenate results in increased expression of WNT5A mRNA21795629
C017947sodium arsenitesodium arsenite results in decreased expression of WNT5A mRNA12679051
C017947sodium arsenitesodium arsenite results in increased expression of WNT5A mRNA20886546
D012999SomanSoman results in decreased expression of WNT5A mRNA19281266
D053260SootSoot results in decreased expression of WNT5A mRNA26551751
D013629Tamoxifen[Tamoxifen co-treated with ESR2 protein] results in decreased expression of WNT5A mRNA19059307
C047246temozolomideWNT5A mRNA affects the susceptibility to temozolomide16365179
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of WNT5A mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of WNT5A mRNA20106945
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of WNT5A mRNA19619570|2180250
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of WNT5A protein21802500
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of WNT5A mRNA20067830
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of WNT5A mRNA24680724
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of WNT5A mRNA17586704|1993321
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased secretion of WNT5A protein26572662
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased expression of WNT5A mRNA23349696
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased expression of WNT5A protein23349696
D014028Tobacco Smoke PollutionWNT5A protein affects the susceptibility to Tobacco Smoke Pollution23349696
D014028Tobacco Smoke Pollution[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of WNT5A mRNA24096154
D014212TretinoinTretinoin results in increased expression of WNT5A mRNA21934132
D014212TretinoinTretinoin results in decreased expression of WNT5A mRNA16604517
C011559tributyltintributyltin results in decreased expression of WNT5A mRNA28011154
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of WNT5A mRNA24935251
C012589trichostatin Atrichostatin A results in increased expression of WNT5A mRNA24935251|2627250
C057693troglitazonetroglitazone results in increased expression of WNT5A mRNA19140230
D014415TunicamycinTunicamycin results in increased expression of WNT5A mRNA17127020
C113580U 0126U 0126 results in increased expression of WNT5A mRNA17320366
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of WNT5A mRNA23179753|2438349
D014635Valproic AcidValproic Acid affects the expression of WNT5A mRNA17292431
D014638VanadatesVanadates results in increased expression of WNT5A mRNA22714537
C029297vinylidene chloridevinylidene chloride results in decreased expression of WNT5A mRNA26682919
D014800VitalliumVitallium analog results in increased expression of WNT5A mRNA23825117
D002762CholecalciferolCholecalciferol results in increased expression of WNT5A mRNA17170073
C088658zoledronic acidzoledronic acid results in increased expression of WNT5A mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003700DNA-binding transcription factor activity-IMP19847889  
GO:0005109frizzled binding-IBA21873635  
GO:0005109frizzled binding-IPI18174455  
GO:0005109frizzled binding-TAS25424568  
GO:0005115receptor tyrosine kinase-like orphan receptor binding-IPI18287027  
GO:0005125cytokine activity-IEA-  
GO:0005515protein binding-IPI26342861  
GO:0005543phospholipid binding-TAS25424568  
GO:0019904protein domain specific binding-IEA-  
GO:0044212transcription regulatory region DNA binding-IDA19847889  
GO:0048018receptor ligand activity-IC18174455  
GO:1902379chemoattractant activity involved in axon guidance-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000187activation of MAPK activity-IDA20034610  
GO:0001736establishment of planar polarity-IEA-  
GO:0001756somitogenesis-IEA-  
GO:0001837epithelial to mesenchymal transition-IEP12841867  
GO:0001938positive regulation of endothelial cell proliferation-IMP17986384  
GO:0001947heart looping-IEA-  
GO:0002053positive regulation of mesenchymal cell proliferation-IEA-  
GO:0002088lens development in camera-type eye-ISS16258938  
GO:0002741positive regulation of cytokine secretion involved in immune response-IMP18174455  
GO:0003323type B pancreatic cell development-IEA-  
GO:0003402planar cell polarity pathway involved in axis elongation-IEA-  
GO:0003408optic cup formation involved in camera-type eye development-ISS16258938  
GO:0007223Wnt signaling pathway, calcium modulating pathway-IDA19946729  
GO:0007223Wnt signaling pathway, calcium modulating pathway-IMP17986384  
GO:0007223Wnt signaling pathway, calcium modulating pathway-NAS24431302  
GO:0007257activation of JUN kinase activity-IDA20034610  
GO:0007257activation of JUN kinase activity-IMP20032469  
GO:0007411axon guidance-ISS-  
GO:0007442hindgut morphogenesis-IEA-  
GO:0007494midgut development-IEA-  
GO:0008584male gonad development-IEP17848411  
GO:0008595anterior/posterior axis specification, embryo-IEA-  
GO:0010033response to organic substance-IEP17486081  
GO:0010469regulation of signaling receptor activity-IEA-  
GO:0010595positive regulation of endothelial cell migration-IMP17035633  17986384  
GO:0010628positive regulation of gene expression-ISS-  
GO:0010800positive regulation of peptidyl-threonine phosphorylation-IEA-  
GO:0010820positive regulation of T cell chemotaxis-IMP19520808  
GO:0010976positive regulation of neuron projection development-ISS-  
GO:0016055Wnt signaling pathway-IBA21873635  
GO:0016055Wnt signaling pathway-IDA20034610  
GO:0016055Wnt signaling pathway-TAS-  
GO:0021891olfactory bulb interneuron development-ISS-  
GO:0030182neuron differentiation-IBA21873635  
GO:0030182neuron differentiation-ISS-  
GO:0030216keratinocyte differentiation-IEP19399181  
GO:0030324lung development-IEA-  
GO:0030514negative regulation of BMP signaling pathway-IEA-  
GO:0032092positive regulation of protein binding-IEA-  
GO:0032148activation of protein kinase B activity-IDA20034610  
GO:0032729positive regulation of interferon-gamma production-IEA-  
GO:0032755positive regulation of interleukin-6 production-IMP18174455  
GO:0033138positive regulation of peptidyl-serine phosphorylation-IEA-  
GO:0034613cellular protein localization-IDA19177143  
GO:0035567non-canonical Wnt signaling pathway-TAS24449494  
GO:0036342post-anal tail morphogenesis-IEA-  
GO:0036517chemoattraction of serotonergic neuron axon-IEA-  
GO:0036518chemorepulsion of dopaminergic neuron axon-IEA-  
GO:0038031non-canonical Wnt signaling pathway via JNK cascade-IEA-  
GO:0040037negative regulation of fibroblast growth factor receptor signaling pathway-IEA-  
GO:0042060wound healing-IDA19878652  
GO:0042733embryonic digit morphogenesis-IEA-  
GO:0043032positive regulation of macrophage activation-IMP18174455  
GO:0043066negative regulation of apoptotic process-IDA19251946  
GO:0043122regulation of I-kappaB kinase/NF-kappaB signaling-ISS-  
GO:0045080positive regulation of chemokine biosynthetic process-IMP19520808  
GO:0045165cell fate commitment-IBA21873635  
GO:0045198establishment of epithelial cell apical/basal polarity-IEA-  
GO:0045599negative regulation of fat cell differentiation-IMP20032469  
GO:0045732positive regulation of protein catabolic process-IGI12952940  
GO:0045766positive regulation of angiogenesis-IMP17035633  
GO:0045778positive regulation of ossification-IMP20032469  
GO:0045807positive regulation of endocytosis-IEA-  
GO:0045836positive regulation of meiotic nuclear division-IEA-  
GO:0045892negative regulation of transcription, DNA-templated-IDA19277043  
GO:0045893positive regulation of transcription, DNA-templated-IMP19847889  
GO:0045944positive regulation of transcription by RNA polymerase II-IMP18174455  
GO:0048022negative regulation of melanin biosynthetic process-IEA-  
GO:0048146positive regulation of fibroblast proliferation-IDA19251946  
GO:0048341paraxial mesoderm formation-IEA-  
GO:0048570notochord morphogenesis-IEA-  
GO:0048706embryonic skeletal system development-IMP19918918  
GO:0048806genitalia development-IMP19918918  
GO:0048843negative regulation of axon extension involved in axon guidance-IEA-  
GO:0048850hypophysis morphogenesis-IEA-  
GO:0050680negative regulation of epithelial cell proliferation-IEA-  
GO:0050718positive regulation of interleukin-1 beta secretion-IMP18174455  
GO:0050718positive regulation of interleukin-1 beta secretion-ISS-  
GO:0050727regulation of inflammatory response-NAS21857966  
GO:0050729positive regulation of inflammatory response-IMP18174455  
GO:0051092positive regulation of NF-kappaB transcription factor activity-IDA18287027  
GO:0051216cartilage development-IEA-  
GO:0051885positive regulation of timing of anagen-IEA-  
GO:0051964negative regulation of synapse assembly-IEA-  
GO:0060028convergent extension involved in axis elongation-IEA-  
GO:0060029convergent extension involved in organogenesis-IEA-  
GO:0060065uterus development-IEA-  
GO:0060067cervix development-IEA-  
GO:0060068vagina development-IEA-  
GO:0060070canonical Wnt signaling pathway-IEA-  
GO:0060071Wnt signaling pathway, planar cell polarity pathway-TAS24431302  
GO:0060157urinary bladder development-IEA-  
GO:0060324face development-IMP19918918  
GO:0060340positive regulation of type I interferon-mediated signaling pathway-IDA19399181  
GO:0060599lateral sprouting involved in mammary gland duct morphogenesis-IEA-  
GO:0060638mesenchymal-epithelial cell signaling-IEA-  
GO:0060686negative regulation of prostatic bud formation-IEA-  
GO:0060744mammary gland branching involved in thelarche-IEA-  
GO:0060750epithelial cell proliferation involved in mammary gland duct elongation-IEA-  
GO:0060760positive regulation of response to cytokine stimulus-IDA19399181  
GO:0060762regulation of branching involved in mammary gland duct morphogenesis-IEA-  
GO:0060775planar cell polarity pathway involved in gastrula mediolateral intercalation-IEA-  
GO:0060809mesodermal to mesenchymal transition involved in gastrulation-IEA-  
GO:0060907positive regulation of macrophage cytokine production-IMP18174455  
GO:0061024membrane organization-TAS-  
GO:0061036positive regulation of cartilage development-IEA-  
GO:0061347planar cell polarity pathway involved in outflow tract morphogenesis-IEA-  
GO:0061348planar cell polarity pathway involved in ventricular septum morphogenesis-IEA-  
GO:0061349planar cell polarity pathway involved in cardiac right atrium morphogenesis-IEA-  
GO:0061350planar cell polarity pathway involved in cardiac muscle tissue morphogenesis-IEA-  
GO:0061354planar cell polarity pathway involved in pericardium morphogenesis-IEA-  
GO:0062009secondary palate development-IMP18413325  
GO:0070245positive regulation of thymocyte apoptotic process-IEA-  
GO:0071222cellular response to lipopolysaccharide-IEP18174455  
GO:0071277cellular response to calcium ion-IEP18703641  
GO:0071300cellular response to retinoic acid-ISS-  
GO:0071346cellular response to interferon-gamma-IEP18174455  
GO:0071425hematopoietic stem cell proliferation-IDA9787155  
GO:0071560cellular response to transforming growth factor beta stimulus-IEP15040835  
GO:0072201negative regulation of mesenchymal cell proliferation-IDA19878652  
GO:0090009primitive streak formation-IEA-  
GO:0090037positive regulation of protein kinase C signaling-IMP19099253  
GO:0090090negative regulation of canonical Wnt signaling pathway-IDA17976063  
GO:0090090negative regulation of canonical Wnt signaling pathway-IGI12952940  
GO:0090103cochlea morphogenesis-IEA-  
GO:0090179planar cell polarity pathway involved in neural tube closure-IEA-  
GO:0090263positive regulation of canonical Wnt signaling pathway-IEA-  
GO:0090630activation of GTPase activity-IEA-  
GO:0097325melanocyte proliferation-IEA-  
GO:0099054presynapse assembly-TAS24449494  
GO:0099068postsynapse assembly-TAS24449494  
GO:0150012positive regulation of neuron projection arborization-ISS-  
GO:1900020positive regulation of protein kinase C activity-IMP12086864  
GO:1901216positive regulation of neuron death-ISS-  
GO:1902474positive regulation of protein localization to synapse-TAS24449494  
GO:1903827regulation of cellular protein localization-IEA-  
GO:1904469positive regulation of tumor necrosis factor secretion-ISS-  
GO:1904861excitatory synapse assembly-TAS24449494  
GO:1904862inhibitory synapse assembly-TAS24449494  
GO:1904934negative regulation of cell proliferation in midbrain-NAS24431302  
GO:1904938planar cell polarity pathway involved in axon guidance-IEA-  
GO:1904953Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation-NAS24431302  
GO:1904955planar cell polarity pathway involved in midbrain dopaminergic neuron differentiation-TAS22988876  
GO:2000049positive regulation of cell-cell adhesion mediated by cadherin-IEA-  
GO:2000052positive regulation of non-canonical Wnt signaling pathway-IEA-  
GO:2000484positive regulation of interleukin-8 secretion-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS25424568  
GO:0005615extracellular space-IBA21873635  
GO:0005615extracellular space-IDA18703641  19048125  20034610  
GO:0005788endoplasmic reticulum lumen-TAS-  
GO:0005796Golgi lumen-TAS-  
GO:0005886plasma membrane-TAS-  
GO:0009986cell surface-IEA-  
GO:0030665clathrin-coated vesicle membrane-TAS-  
GO:0030666endocytic vesicle membrane-TAS-  
GO:0030669clathrin-coated endocytic vesicle membrane-TAS-  
GO:0070062extracellular exosome-TAS-  
KEGG ID KEGG Term
hsa04310Wnt signaling pathway
hsa04340Hedgehog signaling pathway
hsa04916Melanogenesis
hsa05200Pathways in cancer
hsa05217Basal cell carcinoma
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionIEA
R-HSA-162582Signal TransductionTAS
R-HSA-195721Signaling by WNTIEA
R-HSA-195721Signaling by WNTTAS
R-HSA-199991Membrane TraffickingTAS
R-HSA-201681TCF dependent signaling in response to WNTIEA
R-HSA-201681TCF dependent signaling in response to WNTTAS
R-HSA-3238698WNT ligand biogenesis and traffickingTAS
R-HSA-3238698WNT ligand biogenesis and traffickingIEA
R-HSA-372790Signaling by GPCRIEA
R-HSA-373080Class B/2 (Secretin family receptors)IEA
R-HSA-3772470Negative regulation of TCF-dependent signaling by WNT ligand antagonistsIEA
R-HSA-3858494Beta-catenin independent WNT signalingIEA
R-HSA-3858494Beta-catenin independent WNT signalingTAS
R-HSA-4086398Ca2+ pathwayTAS
R-HSA-4086398Ca2+ pathwayIEA
R-HSA-4086400PCP/CE pathwayIEA
R-HSA-4086400PCP/CE pathwayTAS
R-HSA-4608870Asymmetric localization of PCP proteinsTAS
R-HSA-500792GPCR ligand bindingIEA
R-HSA-5099900WNT5A-dependent internalization of FZD4TAS
R-HSA-5140745WNT5A-dependent internalization of FZD2, FZD5 and ROR2TAS
R-HSA-5653656Vesicle-mediated transportTAS
R-HSA-8856825Cargo recognition for clathrin-mediated endocytosisTAS
R-HSA-8856828Clathrin-mediated endocytosisTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23349696Wnt5a is associated with cigarette smoke-related lung carcinogenesis via protein kinase C. (2013)Whang YMPLoS One
28521453Nicotine may promote tongue squamous cell carcinoma progression by activating the Wnt/beta-catenin and Wnt/PCP signaling pathways. (2017 May)Wang COncol Lett
23459936Exploring the genetic basis of chronic periodontitis: a genome-wide association study. (2013 Jun 1)Divaris KHum Mol Genet
22966878Vitamin D intake is negatively associated with promoter methylation of the Wnt antagonist gene DKK1 in a large group of colorectal cancer patients. (2012)Rawson JBNutr Cancer